Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

ruxolitinib

- PMLiVE

UCB releases new data on Bimzelx for hidradenitis suppurativa

The disease affects around 1% of the population in most studied countries

- PMLiVE

InflaRx reports positive phase 2 results for HS and CSU treatments

Topline results demonstrated treatment efficacy for both conditions

- PMLiVE

UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects approximately one in every 100 people in the US

- PMLiVE

UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa

The inflammatory skin disease affects about 1% of the population in most studied countries

- PMLiVE

Acelyrin shares positive phase 3 results for izokibep in hidradenitis suppurativa

Despite the promising readout, the company said it will not be moving forward with the candidate in the inflammatory skin condition

- PMLiVE

Incyte and Syndax’s Niktimvo granted FDA approval in chronic graft versus host disease

Approximately 42% of patients receiving an allogeneic stem cell transplant will develop the condition

- PMLiVE

LEO Pharma, Allergy UK and CHE Taskforce survey reveals burden of chronic hand eczema

The painful inflammatory skin condition, hand eczema, affects up to 14% of the UK population

- PMLiVE

UCB’s Bimzelx granted MHRA approval to treat hidradenitis suppurativa in adults

The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy

- PMLiVE

Incyte announces agreement to acquire Escient Pharmaceuticals for $750m

The deal includes an MRGPRX2 antagonist with the potential to treat multiple mast cell-mediated diseases

- PMLiVE

UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults

The regulator’s decision marks Bimzelx’s fourth approved indication within the EU

- PMLiVE

UCB’s Bimzelx recommended by CHMP to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects an estimated 1% of the population in most studied countries

- PMLiVE

Incyte’s JAK inhibitor cream Opzelura shows promise in hidradenitis suppurativa

The treatment already holds approvals in non-segmental vitiligo and atopic dermatitis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links